Background to the Debate
Isotretinoin is an effective treatment for severe acne, a condition which can be physically, emotionally, and socially disabling. Because the drug is teratogenic, causing severe birth defects, women taking the drug are directed to avoid pregnancy. In the United States, a series of risk reduction programs have been implemented that aim to prevent pregnant women from taking the drug and to prevent women taking it from getting pregnant. The most recent, and most stringent, is an Internet-based, performance-linked system called iPLEDGE, which tries to ensure that the drug is dispensed only when there is documentary proof that the patient is not pregnant and is using two forms of birth control. Is iPLEDGE the best way to reduce isotretinoin birth defects, or is it an unproven and overly burdensome system?
Citation: Abroms L, Maibach E, Lyon-Daniel K, Feldman SR (2006) What Is the Best Approach to Reducing Birth Defects Associated with Isotretinoin? PLoS Med 3(11): e483. https://doi.org/10.1371/journal.pmed.0030483
Published: November 21, 2006
Copyright: © 2006 Abroms et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: LA, EM, and KL-D state that they received no specific funding to write their viewpoint. SRF states that the Center for Dermatology Research is supported by an educational grant from Galderma Laboratories, L. P. The funder played no role in the preparation of his viewpoint.
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: PPP, Pregnancy Prevention Program; RMP, risk management program; SMART, System to Manage Accutane Related Teratogenicity
Lorien Abroms, Edward Maibach, and Katherine Lyon-Daniel's Viewpoint: The Case for Information and Performance-Linked Systems
Untreated acne can be the cause of both significant physical and psychological sequelae . Untreated acne has been associated with difficulties in interpersonal relationships , poor employment prospects , and suicide . But acne treatment itself can also cause harm.
Isotretinoin—which is effective in the treatment of severe recalcitrant nodular acne —is highly teratogenic. Pregnancies exposed to isotretinoin are at significant risk of serious malformations [6,7]. Since introduction of the drug in 1982, over 2,000 pregnancies have been exposed to isotretinoin, most resulting in spontaneous or elective abortions . Other risks to patients from isotretinoin use include increased risk of depression and suicide, liver damage, and musculoskeletal symptoms [5,9].
Isotretinoin is widely prescribed: each year, over 1.4 million isotretinoin prescriptions are dispensed in the United States . About half of all prescriptions go to females , most of whom are in their reproductive years . Many of the prescriptions written for isotretinoin appear to be written “off label”—either as a first-line treatment for severe acne  or as treatment for mild to moderate cases of acne .
A number of increasingly strenuous risk management programs (RMPs) have been implemented since isotretinoin's introduction. These programs aim to prevent pregnant women from taking the drug and to prevent women taking it from getting pregnant. The newest of these programs, iPLEDGE (Figure 1), became mandatory in the US on March 1, 2006. This program represents the most rigorous risk management program in history for such a widely prescribed drug, involving patients, physicians, pharmacies, and wholesalers .
iPLEDGE is a “comprehensive program to help you get prepared, plan your treatments, and ensure you don't get pregnant during the course of isotretinoin therapy” (https://www.ipledgeprogram.com). (Figure: Covance Inc.)
In this article we provide a brief history and analysis of isotretinoin RMPs implemented over the past 20 years (summarized in Table 1), which offer general lessons about the effective use of health information and performance requirements. Additionally, we discuss our concerns with the existing iPLEDGE program and provide some suggestions for improving it.
Overview of History of Isotretinoin (Accutane) Risk Management Approaches
The health and risk communication literature and the broader health behavior literature makes clear that provision of health information has value only to the extent that it is clearly delivered, understood, accepted, and remembered by members of its intended audience [14,15]. Even when these conditions are met, health information influences subsequent health actions only to the extent that recipients are motivated to comply, have a strong belief in their ability to perform the recommended behaviors (i.e., high self-efficacy), and have the skills necessary to perform the behavior in real-world contexts [16,17]. To be effective, behavioral RMPs must ensure that all of these conditions are met, or they must have means to enforce the performance of the behavior.
First-Generation Approach to Risk Management: 1982–1987
Accutane, the first approved form of isotretinoin, was brought to market by Hoffman-La Roche (Roche) in September 1982. Anticipating teratogenic effects based on animal research, Roche distributed the drug with a warning on its Food and Drug Administration (FDA)–approved professional package insert and a patient brochure which warned against pregnancy.
By October 1983, Roche had received seven reports of Accutane-caused fetal malformations. Roche took steps to heighten the strength of the pregnancy warning: language about the drug's teratogenic potential was placed in bold on the package insert; warning letters were sent to prescribers; and red warning stickers were sent to pharmacists and wholesalers to be placed on the drug bottles .
Second-Generation Approach to Risk Management: 1988–2001
Reports of fetal malformations continued, leading the FDA in 1988 to call for a stronger RMP . As a result, Roche developed the Pregnancy Prevention Program (PPP). PPP was a comprehensive educational program which included materials for the prescriber to use in counseling the female patient about the importance of avoiding pregnancy while taking Accutane. Changes in the labeling and packaging included the addition of an icon intended to communicate the need to avoid pregnancy and a “black box” warning on the package insert . More significantly, the program required that prescribing physicians make three risk management procedures mandatory for all female patients as a precondition for prescribing: the signing of a patient consent form, the taking of a pregnancy test seven days prior to beginning treatment, and the selection of two reliable forms of birth control (unless patients indicated that they were abstinent). While these procedures were labeled as “requirements” for prescribing Accutane on the package insert, no mechanism was put in place to enforce that they were carried out. To facilitate the program's implementation, Roche provided prescribing physicians with forms and educational materials to use in counseling patients.
A Roche-sponsored evaluation of the PPP program, which was based on a voluntary sample of female Accutane patients, found that 99% of patients recalled having been told to avoid pregnancy . However, 36% of patients failed to receive a pregnancy test prior to starting therapy, and 15% did not recall being told to use birth control for one month prior to starting therapy . The pregnancy rate was found to be 3.4 pregnancies per 1,000 courses of isotretinoin . A later study found the pregnancy rate had been reduced to 2.8 per 1,000, still resulting in scores of exposed pregnancies each year . In a separate study of 14 Accutane-exposed pregnancies, eight women were found to have used no contraception at all, and another five used only one method, when two were recommended . In evaluating the program's success, the FDA concluded that the voluntary and information-based RMP was not sufficiently effective in influencing the contraceptive behavior of female patients and in reducing the number of exposed pregnancies .
Third-Generation Approach to Risk Management: 2002–2005
In 2002, the FDA called for further revisions to the risk management program for Accutane and other more recently approved generic versions . The FDA mandated that a medication guide —a written drug information sheet—be given to patients by pharmacists along with all new and refill prescriptions of isotretinoin. Building on its PPP, Roche created SMART (System to Manage Accutane Related Teratogenicity), which upgraded the risk management practices to include improved education for female patients and two negative pregnancy tests. It also included a novel risk management tool: the required use of a yellow qualification sticker on all prescriptions issued. The qualification stickers—which were to be filled out by prescribers and placed on prescriptions—were intended to serve as a reminder to prescribers of their responsibilities in insuring that female patients were qualified for isotretinoin (i.e., that they had been given two pregnancy tests and found not to be pregnant, and that they had chosen two forms of birth control). While prescribers were sent the qualification stickers only after signing a letter which detailed qualification requirements, no enforcement mechanism was put in place to insure that prescribers gave qualification stickers only to patients who were truly eligible. Pharmacists were required to fill only those Accutane prescriptions with an affixed sticker . All of the generic manufacturers fielded similar risk management programs.
An evaluation of the SMART program found that 98% of women taking Accutane knew to avoid pregnancy  and 92% recalled having received a prescription with a qualification sticker . However, of women at risk for pregnancy, 34% failed to receive the required two pregnancy tests . Of women who were at risk for pregnancy and non-abstinent, 54% did not use two forms of birth control . More importantly, the pregnancy rate did not decline substantially below that achieved under the PPP . Thus, while the inclusion of a reminder system—the use of the yellow qualification stickers—did increase the proportion of women who took pregnancy tests and used appropriate birth control , these changes fell short of expectations and did not lead to a sufficient reduction in the number of exposed pregnancies. Although the evaluations of this RMP were not able to pinpoint the reasons for shortcomings in the system performance, prescriber under-compliance with qualification requirements and patients' lack of motivation, selfefficacy, and/or ability to use two forms of contraception throughout the course of treatment were likely contributors.
Fourth-Generation Approach to Risk Management: 2005–Current
SMART's limited success in further reducing isotretinoin-exposed pregnancies led the FDA to request that Roche and other isotretinoin manufacturers create a more rigorous performance-linked RMP. Stringent performance-linked programs have been used for a handful of drugs including thalidomide and clozapine, though none of these are as widely prescribed as isotretinoin. In response to the request, all four manufacturers collaborated to create the iPLEDGE program.
iPLEDGE requires that all parties in the distribution chain (i.e., health-care professionals who prescribe isotretinoin, pharmacies that dispense isotretinoin, and wholesalers that distribute isotretinoin) and all patients receiving prescriptions—male and female—register in a single database online (https://www.ipledgeprogram.com) or by telephone. Prior to dispensing to females, providers must enter the results of two negative pregnancy tests, and specify two forms of contraception that the patient agrees to use, and must on a monthly basis administer and verify the negative results of pregnancy tests, provide additional pregnancy prevention counseling, and re-identify the patient's contraceptive choices. Prior to receiving their medication, patients must register with the system, sign a consent form, and identify their two forms of birth control. On a monthly basis, they must indicate their two forms of contraception (which must match the provider's entry) and must answer questions which demonstrate their knowledge of the teratogenic effects of isotretinoin. Pharmacists are permitted to dispense only if the web-based system shows that the patient and provider have complied with all requirements of the system.
iPLEDGE represents the most rigorous risk management program in history for such a widely prescribed drug.
As the program is relatively new, there has been no formal evaluation of iPLEDGE to date. According to FDA reports, the program appears to have been widely adopted. Between December 30, 2005 and March 23, 2006, 22,000 prescribers and 71,700 patients registered with iPLEDGE . However, based on news reports, the program has not been well received, especially by dermatologists, the primary prescribers of isotretinoin . Dermatologists have complained that the new program is inflexible and confusing, and has too many requirements. Many were frustrated initially by technical glitches from the Web-based system coupled with inadequate telephone support . There have also been reports of patients having difficulty in complying with the system's numerous requirements .
The Advantages of iPLEDGE
iPLEDGE has the potential to improve upon the previous RMPs by identifying existing pregnancies before treatment has begun, by detecting new, unplanned pregnancies earlier, and by increasing patients' knowledge and motivation about the importance of complying with program requirements. Under iPLEDGE, prescribers must ensure two negative pregnancy tests before a patient can start treatment. This represents a significant improvement because under SMART, over one-third of women did not receive these tests , and an estimated 13% of exposed pregnancies existed prior to the start of treatment . Furthermore, requiring monthly pregnancy tests, pledging in advance to use two forms of birth control, and the myriad monthly reminders received by both patients and prescribers when they log onto the iPLEDGE system should have a beneficial effect on a patient's motivation to comply.
Effective use of contraception requires knowledge, motivation, skill, and for some methods, a high degree of self-efficacy . Under SMART, the most commonly reported reasons for pregnancy during isotretinoin therapy were unsuccessful attempts at abstinence, use of ineffective contraception, inconsistent use of contraception, unexpected sexual activity, and contraceptive failure . It remains an open question the degree to which iPLEDGE will result in better pregnancy prevention skills, higher levels of self-efficacy about pregnancy prevention and, ultimately, pregnancies prevented.
Concerns about iPLEDGE
Despite the advantages of iPLEDGE, we have several concerns about the new program. Some patients who have insufficient skills in using contraceptives will be in the care of providers (in most cases dermatologists) who may not have time or sufficient knowledge to counsel their patients about contraceptive use. Some patients, especially teenagers, who represent a significant proportion of isotretinoin users, will be unwilling to communicate openly with their health-care provider about their sexual activity . Some patients are likely to be insufficiently motivated to follow through with their plans to use two forms of contraception for every sexual episode over a five to six month course of treatment. Furthermore, as isotretinoin remains widely available over the Internet without a prescription , many people will obtain isotretinoin outside of the iPLEDGE RMP. This problem may increase as people try to avoid the stringent requirements that are part of iPLEDGE.
Also of concern is that the iPLEDGE program may have been suboptimally designed, and as a result, may place an unnecessary burden on patients and providers. Core principles of program design and development dictate that: (1) programs should be developed with much input from the end-users of the systems—in this case prescribers, patients, pharmacies, and wholesalers; (2) programs should receive extensive user testing before being released to the public; and (3) programs should be developed and maintained within a context of total quality management . These basic principles appear to have been somewhat violated in the development of iPLEDGE.
Prior to the program's release, limited input was solicited from the iPLEDGE Scientific Advisory Board, a group formed in early 2005 to represent the various stakeholder groups. The program became mandatory before it was sufficiently tested, and users who were required to use the system were initially faced with navigating through technical problems and computer glitches . It remains to be seen the degree to which principles of total quality management—including a strong focus on process measurement and continuous improvements—will be embraced.
Ways to Improve iPLEDGE
We see several opportunities to improve iPLEDGE to address some of these concerns. The fact that iPLEDGE is managed primarily via a Web site presents excellent opportunities for tailored and multimedia patient education that currently have not been embraced. As designed, the Web site's primary function is data entry. The site currently contains a minimal amount of patient education material, and the information present is exclusively text-based, presented in 9 point font, and written at a 12th grade reading level, which is substantially higher than the ability of the average adult .
We recommend the addition of appropriate multimedia educational content to: (1) reinforce important information (i.e., the risks associated with isotretinoin and the need for two forms of contraception), and perhaps more importantly, (2) provide an effective means of conveying difficult or sensitive information that is not otherwise being effectively communicated (e.g., information on various contraceptive methods and how to appropriately use them, complete with animation/video to model various techniques). Furthermore, we recommend audience testing the Web site with all categories of users—current isotretinoin patients, prescribers, and pharmacists—to ensure that the content of the Web site is clearly communicated, easy to use, and meaningful. It may also be necessary to simplify the program requirements so that there is less burden on patients and providers, and less incentive for patients to circumvent program procedures.
The required monthly knowledge-check questions in iPLEDGE—intended to determine if the patient understands the need for two forms of birth control and the potential of isotretinoin to cause birth defects—is a novel approach to encouraging patient compliance. However, given that nearly all patients said they understood they were not supposed to get pregnant under the previous RMPs [8,22,23], a more appropriate focus for these questions is to ensure that patients have actionable knowledge about pregnancy prevention and are properly using the contraceptive methods that they selected. Incorrect responses should elicit presentation of appropriate educational material.
By adding an e-mail function, iPLEDGE could automatically generate and send tailored reminders and other relevant information to patients. (For phone users, this information could be available via regular mail). Such proactive contacts might be especially valuable in reminding patients of the need for pregnancy prevention during the one month interval after therapy ends when many patients will lose contact with iPLEDGE. Under SMART, 32% of Accutane-exposed pregnancies occurred during this post-therapy period .
We believe an important general lesson from evaluations of isotretinoin RMPs is that RMPs need to be designed with input from users in all phases of a program's development. Furthermore, information alone may not be sufficient to manage behavior-based medical risks, especially when mitigating those risks requires that the behaviors be performed consistently, and with considerable motivation and skill, over long periods of time. Having program “requirements” in the absence of enforcement mechanisms for those requirements may not be sufficient to manage these types of medical risks. Finally, information and performance-linked approaches should not been seen as either/or alternatives, but complements in achieving sustained behavior change.
The Case for Performance-Linked Systems
While performance-linked systems undoubtedly place a burden on everyone in the system, from a risk management perspective, there is a compelling case to be made for them. For example, Directly-Observed Treatment Short-Course (DOTS) has become the internationally recommended tuberculosis control strategy despite the demands it places on patients and the health-care system. The performance of iPLEDGE will likely influence a dialogue about whether the demands it places on patients and the health-care system are tolerable, and whether performance-linked systems should be extended to other medications when the potential negative consequences to patients, their offspring, or society at large are severe.
Steven R. Feldman's Viewpoint: A Balanced Approach May Be The Best Way To Reduce Isotretinoin Birth Defects
Acne can disfigure patients physically and emotionally, while disabling them socially. This inflammatory disease can have a dramatic impact on patients' lives . In the not-too-distant past, there was little dermatologists could do for patients with the most severe forms. Now, patients (and their parents) do not need to suffer the physical and emotional scars of acne. For even the most severely affected patients, the disease is treatable, even curable, with isotretinoin.
Unfortunately, isotretinoin is not without side effects. Patients must be warned about the rare risk of severe depression. While I am convinced this rare side effect is real, isotretinoin probably prevents more depression in teens than it causes [32,33]. More important is the risk of birth defects occurring when a fetus is exposed to isotretinoin. Isotretinoin is a powerful teratogen used in the treatment of a disease that occurs in young women of child-bearing potential. Physicians, and these patients, bear a heavy responsibility when using isotretinoin.
The benefits accrued to society from using isotretinoin outweigh the risks.
Under guidance from the FDA, isotretinoin manufacturers have instituted increasingly stringent programs to prevent isotretinoin-exposed pregnancies. Whether any of these programs have substantially reduced isotretinoin-exposed pregnancies beyond the efforts already taken by physicians in the care of their patients is not known . It is difficult for me to believe that any one-size-fits-all program could be more effective in preventing pregnancy than the careful efforts of a physician working with their patient. But when it comes to preventing birth defects, I'm glad for any help I can get.
Unfortunately, we don't know whether even the most stringent pregnancy prevention program so far, iPLEDGE, reduces the rate of exposed pregnancies. The pregnancy prevention programs have been based largely on monthly pregnancy testing. The history of the isotretinoin pregnancy prevention programs and a recent retrospective study show that pregnancy testing doesn't prevent pregnancy . I sometimes wonder if doing this testing gives some patients a cavalier attitude based on the false impression that catching pregnancies early will prevent isotretinoin-induced birth defects. Catching an exposed pregnancy early does not prevent isotretinoin teratogenicity. It is essential to make sure patients don't get pregnant in the first place.
One strength of iPLEDGE is accountability. At the very least, iPLEDGE will help prevent the 13% of exposed pregnancies that occur when someone who was already pregnant takes the drug. But iPLEDGE also has many weaknesses. The program was implemented without any testing to determine whether it actually reduces pregnancy risk. Beyond that, the hassles of the program leave less time to focus on the single most important message: you must not become pregnant while isotretinoin is in your body.
The apparently untested recommendations for improving iPLEDGE described by Abroms et al. may help, but they may not. A lesson from the history of past programs is that new programs should be tested before implementation. Until then, physicians must continue to use isotretinoin with great caution. Isotretinoin should be a last-line acne treatment for women of child-bearing potential. Typically, these women should first be treated with a combination of topical antibiotics and retinoids , oral antibiotics (probably a second one if the first doesn't work), and birth control pills for several months before using isotretinoin. Birth control pills are an effective, FDA-approved treatment for acne in women. By using them first, some isotretinoin use might be averted altogether. If isotretinoin is still necessary, the woman will already have been on birth control pills for several months and will have had time for education about the drug and proper (and, we all hope, effective) pregnancy prevention counseling.
When treating a patient with severe acne unresponsive to other treatments, having access to isotretinoin is a godsend. Perhaps some people believe that even one isotretinoin-induced birth defect is too many and think that isotretinoin use should be stopped altogether. Stopping birth defects is an emotionally powerful goal. Yet dermatologists often see patients with horrific scars from acne, patients whose suffering could have been prevented by early treatment with isotretinoin.
There are both risks and benefits to isotretinoin. There has been some effort to quantify and compare these risks and benefits . Despite patients' and physicians' efforts at pregnancy prevention, there are still a limited number of fetal isotretinoin exposures. Yet because acne is so horrific and so common, even the most conservative risk/benefit analysis finds that, overall, isotretinoin provides far more benefit than risk. Even if it were used for milder forms of acne, the benefits accrued to society from using isotretinoin outweigh the risks in quantitative analyses. While everyone (patients, their families, physicians, the media, interest groups, and politicians) would like to see the risk of isotretinoin-induced birth defects reduced to the lowest possible level, those who see the benefits of isotretinoin do not want patients to suffer (and suffer greatly) by losing isotretinoin entirely.
- 1. Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN (2002) Acne therapy: A methodologic review. J Am Acad Dermatol 47: 231–240.HP LehmannKA RobinsonJS AndrewsV. HollowaySN Goodman2002Acne therapy: A methodologic review.J Am Acad Dermatol47231240
- 2. Jewett S, Ryan T (1985) Skin disease and handicap: An analysis of the impact of skin conditions. Soc Sci Med 20: 425–429.S. JewettT. Ryan1985Skin disease and handicap: An analysis of the impact of skin conditions.Soc Sci Med20425429
- 3. Cunliffe WJ (1986) Acne and unemployment. Br J Dermatol 115: 386.WJ Cunliffe1986Acne and unemployment.Br J Dermatol115386
- 4. Cotterill JA, Cunliffe WJ (1997) Suicide in dermatological patients. Br J Dermatol 137: 246–250.JA CotterillWJ Cunliffe1997Suicide in dermatological patients.Br J Dermatol137246250
- 5. Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, et al. (1984) Isotretinoin therapy for acne: Results of a multicenter dose-response study. J Am Acad Dermatol 10: 490–496.JS StraussRP RapiniAR ShalitaE. KoneckyPE Pochi1984Isotretinoin therapy for acne: Results of a multicenter dose-response study.J Am Acad Dermatol10490496
- 6. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, et al. (1985) Retinoic acid embryopathy. N Engl J Med 313(14): 837–841.EJ LammerDT ChenRM HoarND AgnishPJ Benke1985Retinoic acid embryopathy.N Engl J Med31314837841
- 7. Mitchell AA, Van Bennekom CM, Louik C (1995) A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 333: 101–106.AA MitchellCM Van BennekomC. Louik1995A pregnancy-prevention program in women of childbearing age receiving isotretinoin.N Engl J Med333101106
- 8. Lindstrom J (2004) Isotretinoin: Background and regulatory history. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting. J. Lindstrom2004Isotretinoin: Background and regulatory history. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting.February 26–27, 2004. Available: http://www.fda.gov/ohrms/dockets/ac/04/slides/4017s1.htm. Accessed 13 October 2006. February 26–27, 2004. Available: http://www.fda.gov/ohrms/dockets/ac/04/slides/4017s1.htm. Accessed 13 October 2006.
- 9. Wysowski DK, Pitts M, Beitz J (2001) An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 45: 515–519.DK WysowskiM. PittsJ. Beitz2001An analysis of reports of depression and suicide in patients treated with isotretinoin.J Am Acad Dermatol45515519
- 10. Stern RS (2000) Medication and medical service utilization for acne 1995–1998. J Am Acad Dermatol 43: 1042–1048.RS Stern2000Medication and medical service utilization for acne 1995–1998.J Am Acad Dermatol4310421048
- 11. Chen K, White TJ, Juzba M, Chang E (2002) Oral isotretinoin: An analysis of its utilization in a managed care organization. J Manag Care Pharm 8: 272–277.K. ChenTJ WhiteM. JuzbaE. Chang2002Oral isotretinoin: An analysis of its utilization in a managed care organization.J Manag Care Pharm8272277
- 12. Wysowski DK, Swann J, Vega A (2002) Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000. J Am Acad Dermatol 46: 505–509.DK WysowskiJ. SwannA. Vega2002Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000.J Am Acad Dermatol46505509
- 13. Food and Drug Administration (2006) iPLEDGE update. Food and Drug Administration2006iPLEDGE update.Available: http://www.fda.gov/cder/drug/infopage/accutane/iPLEDGEupdate200603.htm. Accessed 18 October 2006. Available: http://www.fda.gov/cder/drug/infopage/accutane/iPLEDGEupdate200603.htm. Accessed 18 October 2006.
- 14. McGuire WJ (1984) Public communication as a strategy for inducing health-promoting behavioral change. Prev Med 13: 299–319.WJ McGuire1984Public communication as a strategy for inducing health-promoting behavioral change.Prev Med13299319
- 15. Synder LB, Hamilton MA, Mithchell EW, Kiwanuka-Tondo J, Fleming-Milici F, et al. (2004) A meta-analysis of the effect of mediated health communication campaigns on behavior change in the United States. J Health Commun 9(Suppl 1): 71–96.LB SynderMA HamiltonEW MithchellJ. Kiwanuka-TondoF. Fleming-Milici2004A meta-analysis of the effect of mediated health communication campaigns on behavior change in the United States.J Health Commun9Suppl 17196
- 16. Bandura A (1986) Social foundations of thought and action: A social cognitive theory. Englewood Cliffs (NJ): Prentice-Hall. 544 p.A. Bandura1986Social foundations of thought and action: A social cognitive theory.Englewood Cliffs (NJ)Prentice-Hall544
- 17. Glanz K, Rimer BK, Lewis FM, editors. (2002) Health behavior and health education: Theory, research and practice. 3rd edition. San Francisco: Jossey-Bass. 624 p.K. GlanzBK RimerFM Lewiseditors. 2002Health behavior and health education: Theory, research and practice3rd editionSan FranciscoJossey-Bass624 editors.
- 18. Food and Drug Administration (1983) Food and Drug Administration1983Dermatologic Drugs Advisory Committee Transcript: October 21, 1983. Available: http://www.fda.gov/ohrms/dockets/ac/accutane.htm. Accessed 18 October 2006. Dermatologic Drugs Advisory Committee Transcript: October 21, 1983. Available: http://www.fda.gov/ohrms/dockets/ac/accutane.htm. Accessed 18 October 2006.
- 19. Food and Drug Administration (1988) Dermatologic Drugs Advisory Committee Transcript: April 26, 1988. Food and Drug Administration1988Dermatologic Drugs Advisory Committee Transcript: April 26, 1988.Available: http://www.fda.gov/ohrms/dockets/ac/accutane.htm. Accessed 18 October 2006. Available: http://www.fda.gov/ohrms/dockets/ac/accutane.htm. Accessed 18 October 2006.
- 20. Perlman SE, Leach EE, Dominguez L, Ruszkowski AM, Rudy SJ (2001) “Be smart, be safe, be sure”. The revised Pregnancy Prevention Program for women on isotretinoin. J Reprod Med 46(Suppl 2): 179–185.SE PerlmanEE LeachL. DominguezAM RuszkowskiSJ Rudy2001“Be smart, be safe, be sure”. The revised Pregnancy Prevention Program for women on isotretinoin.J Reprod Med46Suppl 2179185
- 21. Honein MA, Paulozzi LJ, Erickson JD (2001) Continued occurrence of Accutane-exposed pregnancies. Teratology 64: 142–147.MA HoneinLJ PaulozziJD Erickson2001Continued occurrence of Accutane-exposed pregnancies.Teratology64142147
- 22. Brinker A, Kornegay C, Nourjah P (2005) Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies. Arch Dermatol 141: 563–569.A. BrinkerC. KornegayP. Nourjah2005Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies.Arch Dermatol141563569
- 23. Shiff SA (2004) Overview of SMART Program. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting. SA Shiff2004Overview of SMART Program. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting.February 26–27, 2004. Available: http://www.fda.gov/ohrms/dockets/ac/04/slides/4017s1.htm. Accessed 18 October 2006. February 26–27, 2004. Available: http://www.fda.gov/ohrms/dockets/ac/04/slides/4017s1.htm. Accessed 18 October 2006.
- 24. Darves B (2006 March 9) Dermatologists frustrated with problematic iPledge program. Medscape Medical News. B. Darves2006 March 9Dermatologists frustrated with problematic iPledge program. Medscape Medical News.Available: http://www.medscape.com/viewarticle/525664. Accessed 18 October 2006. Available: http://www.medscape.com/viewarticle/525664. Accessed 18 October 2006.
- 25. Harris G (2006 February 11) System said to fail to steer women from acne drug. The New York Times. G. Harris2006 February 11System said to fail to steer women from acne drug.The New York TimesAvailable: http://www.nytimes.com/2006/02/11/national/11inhibit.html. Accessed 18 October 2006. Available: http://www.nytimes.com/2006/02/11/national/11inhibit.html. Accessed 18 October 2006.
- 26. Huber MH (2004) Review of Data from SMART Program. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting. MH Huber2004Review of Data from SMART Program. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting.February 26–27, 2004. Available: http://www.fda.gov/ohrms/dockets/ac/04/slides/4017s1.htm. Accessed 18 October 2006. February 26–27, 2004. Available: http://www.fda.gov/ohrms/dockets/ac/04/slides/4017s1.htm. Accessed 18 October 2006.
- 27. Brown SS, Eisenberg L, editors. (1995) The best intentions: Unintended pregnancy and the well-being of children and families. Washington (D. C.): National Academy Press. 392 p.SS BrownL. Eisenbergeditors. 1995The best intentions: Unintended pregnancy and the well-being of children and familiesWashington (D. C.)National Academy Press392 editors.
- 28. Honein MA, Moore CA, Erickson JD (2004) Can we ensure the safe use of known human teratogens? Drug Saf 27: 1069–1080.MA HoneinCA MooreJD Erickson2004Can we ensure the safe use of known human teratogens?Drug Saf2710691080
- 29. Andreasen AR (1995) Marketing social change: Changing behavior to promote health, social development, and the environment. San Francisco: Jossey-Bass. 368 p.AR Andreasen1995Marketing social change: Changing behavior to promote health, social development, and the environmentSan FranciscoJossey-Bass368
- 30. Doak CC, Doak LG, Root JH (1996) Teaching patients with low literacy skills. Philadelphia: Lippincott. CC DoakLG DoakJH Root1996Teaching patients with low literacy skillsPhiladelphiaLippincott
- 31. Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, et al. (2004) A catalog of dermatology utilities: A measure of the burden of skin diseases. J Investig Dermatol Symp Proc 9: 160–168.SC ChenAM BayoumiSL SoonK. AftergutP. Cruz2004A catalog of dermatology utilities: A measure of the burden of skin diseases.J Investig Dermatol Symp Proc9160168
- 32. Rohrback JM, Fleischer AB Jr, Krowchuk DP, Feldman SR (2004) Depression is not common in isotretinoin-treated acne patients. J Dermatolog Treat 15: 252.JM RohrbackAB Fleischer JrDP KrowchukSR Feldman2004Depression is not common in isotretinoin-treated acne patients.J Dermatolog Treat15252
- 33. Jick SS, Kremers HM, Vasilakis-Scaramozza C (2000) Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 136: 1231–1236.SS JickHM KremersC. Vasilakis-Scaramozza2000Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide.Arch Dermatol13612311236
- 34. Fleischer AB Jr, Simpson JK, McMichael A, Feldman SR (2003) Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States? J Am Acad Dermatol 49: 662–666.AB Fleischer JrJK SimpsonA. McMichaelSR Feldman2003Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States?J Am Acad Dermatol49662666
- 35. Cheetham TC, Wagner RA, Chiu G, Day JM, Yoshinaga MA, et al. (2006) A risk management program aimed at preventing fetal exposure to isotretinoin: Retrospective cohort study. J Am Acad Dermatol 55: 442–448.TC CheethamRA WagnerG. ChiuJM DayMA Yoshinaga2006A risk management program aimed at preventing fetal exposure to isotretinoin: Retrospective cohort study.J Am Acad Dermatol55442448
- 36. Thevarajah S, Balkrishnan R, Camacho FT, Feldman SR, Fleischer AB Jr (2005) Trends in prescription of acne medication in the US: Shift from antibiotic to non-antibiotic treatment. J Dermatolog Treat 16: 224–228.S. ThevarajahR. BalkrishnanFT CamachoSR FeldmanAB Fleischer Jr2005Trends in prescription of acne medication in the US: Shift from antibiotic to non-antibiotic treatment.J Dermatolog Treat16224228
- 37. Jordan AY, Parks L, Chen SC, Higgins K, Fleischer AB, et al. (2005) Does the teratogenicity of isotretinoin outweigh its benefits? J Dermatolog Treat 16: 190–192.AY JordanL. ParksSC ChenK. HigginsAB Fleischer2005Does the teratogenicity of isotretinoin outweigh its benefits?J Dermatolog Treat16190192